Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer

Autor: Caroline Mommsen, Harun Ilhan, Stefano Fanti, Wouter V. Vogel, Francis Sundram, Ignasi Carrió, Yong Du, Giuseppe De Vincentis, Val Lewington, Egbert U. Nitzsche, Wim J.G. Oyen
Přispěvatelé: Du Y, Carrio I, De Vincentis G, Fanti S, Ilhan H, Mommsen C, Nitzsche E, Sundram F, Vogel W, Oyen W, Lewington V.
Jazyk: angličtina
Rok vydání: 2017
Předmět:
Male
Oncology
Radium-223
medicine.medical_specialty
Radiumdichloride
Best practice
Nuclearmedicine
Castration resistant
Rare cancers Radboud Institute for Molecular Life Sciences [Radboudumc 9]
Targeted alpha therapy
Ra-223
030218 nuclear medicine & medical imaging
Radium dichloride
03 medical and health sciences
Prostate cancer
0302 clinical medicine
Patient satisfaction
All institutes and research themes of the Radboud University Medical Center
Multidisciplinary approach
Internal medicine
Patient experience
Agency (sociology)
medicine
Humans
castration-resistant prostate cancer . nuclearmedicine . radiumdichloride . ra-223 . targeted alpha therapy
Radiology
Nuclear Medicine and imaging
Neoplasm Metastasis
Expert Testimony
Castration-resistant prostate cancer
business.industry
Patient Selection
Bone metastases
General Medicine
medicine.disease
Bone metastase
Prostatic Neoplasms
Castration-Resistant
Patient Satisfaction
030220 oncology & carcinogenesis
Family medicine
Nuclear medicine
Original Article
business
Radium
medicine.drug
Zdroj: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
Universitat Pompeu Fabra
European Journal of Nuclear Medicine and Molecular Imaging, 44, 10, pp. 1671-1678
European Journal of Nuclear Medicine and Molecular Imaging, 44, 1671-1678
European Journal of Nuclear Medicine and Molecular Imaging
ISSN: 1619-7070
Popis: Purpose Radium Ra 223 dichloride (radium-223, Xofigo (R)) is the first targeted alpha therapy for patients with castration-resistant prostate cancer and symptomatic bone metastases. Radium-223 provides a new treatment option for this setting, but also necessitates a new treatment management approach. We provide straightforward and practical recommendations for European nuclear medicine centres to optimize radium-223 service provision. Methods An independent research consultancy agency observed radium-223 procedures and conducted interviews with all key staff members involved in radium-223 treatment delivery in 11 nuclear medicine centres across six countries (Germany, Italy, the Netherlands, Spain, Switzerland and the UK) experienced in administering radium-223. The findings were collated and discussed at a meeting of experts from these centres, during which key consensus recommendations were defined. Results The recommendations cover centre organization and preparation; patient referral; radium-223 ordering, preparation and disposal; radium-223 treatment delivery/administration; and patient experience. Guidance includes structured coordination and communication within centres and multidisciplinary teams, focusing on sharing best practice to provide high-quality, patient-centred care throughout the treatment pathway. Conclusions These expert recommendations are intended to complement existing management guidelines. Sharing best practice and experience will help nuclear medicine centres to optimize radium-223 service provision and improve patient care.
Databáze: OpenAIRE
Externí odkaz: